[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

FXN Frataxin Restoration Program

Edit / manage →

Friedreich ataxia

IND-enablingActiveGene therapy (AAV)NeurodegenerationMixed· low conf2 evidence-linked claims

Overview

Disease area
Neurodegeneration
Indication
Friedreich ataxiaMONDO:0100339
Mechanism of action
Frataxin expression restoration in dorsal root ganglia
Development stage
IND-enabling
Institution
Greenfield Institute for Rare Disease
Principal investigators
A. Petrov
Targets
FXN
Pathways
Mitochondrial function
Trial registry

Scientific assessment

1 claims
  • Target ValidationStrong

    Frataxin deficiency drives mitochondrial iron-sulfur cluster failure in Friedreich ataxia; restoring expression is mechanistically grounded.

Translational assessment

1 claims
  • EndpointsLimited

    mFARS is the accepted clinical endpoint; DRG-targeted dosing must balance frataxin restoration against overexpression toxicity.

    internalendpoint-2024

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews
Mixed· low confAcademicAtaxia panel2025-01-10
Strengths

Strong mechanistic grounding in frataxin biology.

Weaknesses

Overexpression toxicity window; DRG-targeted delivery unproven.

Improvement areas

Establish therapeutic index in vivo before IND-enabling.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Active
    IND-enabling; therapeutic-index work ongoing.2025-01-10

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.